VIVUS (STU:VIU1) Common Stock : €0.01 Mil (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Common Stock?

VIVUS's quarterly common stock stayed the same from Sep. 2019 (€0.01 Mil) to Dec. 2019 (€0.01 Mil) and stayed the same from Dec. 2019 (€0.01 Mil) to Mar. 2020 (€0.01 Mil).

VIVUS's annual common stock increased from Dec. 2017 (€0.01 Mil) to Dec. 2018 (€0.01 Mil) but then stayed the same from Dec. 2018 (€0.01 Mil) to Dec. 2019 (€0.01 Mil).

VIVUS Common Stock Historical Data

The historical data trend for VIVUS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Common Stock Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Common Stock

Get a 7-Day Free Trial

0.10

0.01

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Common Stock	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

VIVUS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines